Literature DB >> 16420600

The synthetic analogue of mycoplasmal lipoprotein FSL-1 induces dendritic cell maturation through Toll-like receptor 2.

Kazuto Kiura1, Hideo Kataoka, Takashi Nakata, Takeshi Into, Motoaki Yasuda, Shizuo Akira, Nobuo Inoue, Ken-ichiro Shibata.   

Abstract

Granulocyte-macrophage colony-stimulating factor-differentiated bone marrow-derived dendritic cells were stimulated with the synthetic lipopeptide S-(2,3-bispalmitoyloxypropyl)-CGDPKHSPKSF (FSL-1) or the Escherichia coli lipopolysaccharide. FSL-1 induced the production of TNF-alpha and IL-12 by C57BL/6-derived bone marrow-derived dendritic cells but not by bone marrow-derived dendritic cells from Toll-like receptor 2-deficient (TLR2(-/-)) mice. Lipopolysaccharide induced the production of TNF-alpha and IL-12 by bone marrow-derived dendritic cells derived from either type of mice. FSL-1 did not induce production of IL-10 by bone marrow-derived dendritic cells from either type of mice, whereas lipopolysaccharide induced small amounts of IL-10 by bone marrow-derived dendritic cells from both types of mice. The upregulation by FSL-1 of the expression of CD80, CD86 and the MHC class II molecule IA(b) was dose- and time-dependent on the surfaces of C57BL/6-derived bone marrow-derived dendritic cells but not on the surface of TLR2(-/-)-derived bone marrow-derived dendritic cells. Lipopolysaccharide upregulated the expression of these molecules on the surfaces of bone marrow-derived dendritic cells from both types of mice. The expression of CD11c on the surfaces of C57BL/6-derived bone marrow-derived dendritic cells was upregulated by stimulation with both FSL-1 and lipopolysaccharide up to 12 h; thereafter, the expression was downregulated. The results suggest that FSL-1 can accelerate maturation of bone marrow-derived dendritic cells and this FSL-1 activity is mediated by TLR2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16420600     DOI: 10.1111/j.1574-695X.2005.00002.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  13 in total

1.  TLR2 activation inhibits embryonic neural progenitor cell proliferation.

Authors:  Eitan Okun; Kathleen J Griffioen; Tae Gen Son; Jong-Hwan Lee; Nicholas J Roberts; Mohamed R Mughal; Emmette Hutchison; Aiwu Cheng; Thiruma V Arumugam; Justin D Lathia; Henriette van Praag; Mark P Mattson
Journal:  J Neurochem       Date:  2010-04-29       Impact factor: 5.372

2.  Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells.

Authors:  Kuan-Yin Shen; Ying-Chyi Song; I-Hua Chen; Chih-Hsiang Leng; Hsin-Wei Chen; Hui-Ju Li; Pele Chong; Shih-Jen Liu
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

3.  Synthesis and characterization of a dipalmitoylated lipopeptide derived from paralogous lipoproteins of Mycoplasma pneumoniae.

Authors:  Takeshi Into; Jun-ichi Dohkan; Megumi Inomata; Misako Nakashima; Ken-ichiro Shibata; Kenji Matsushita
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

4.  Inflammatory lipoproteins purified from a toxigenic and arthritogenic strain of Mycoplasma arthritidis are dependent on Toll-like receptor 2 and CD14.

Authors:  Akira Hasebe; Hong-Hua Mu; Leigh R Washburn; Fok V Chan; Nathan D Pennock; Michael L Taylor; Barry C Cole
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

5.  The Toll-like receptor 2 (TLR2) ligand FSL-1 is internalized via the clathrin-dependent endocytic pathway triggered by CD14 and CD36 but not by TLR2.

Authors:  Haque M Shamsul; Akira Hasebe; Mitsuhiro Iyori; Makoto Ohtani; Kazuto Kiura; Diya Zhang; Yasunori Totsuka; Ken-ichiro Shibata
Journal:  Immunology       Date:  2010-01-27       Impact factor: 7.397

6.  Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

Authors:  Deepak B Salunke; Seth W Connelly; Nikunj M Shukla; Alec R Hermanson; Lauren M Fox; Sunil A David
Journal:  J Med Chem       Date:  2013-07-10       Impact factor: 7.446

7.  Design, Synthesis, and Preliminary Immunological Studies of MUC1-Based Antitumor Vaccines Adjuvanted with R- and S-FSL-1.

Authors:  Yonghui Liu; Bocheng Yan; Zhaoyu Wang; Haomiao Zhu; Xiaona Yin; Kun Wang; Menglei Wang; Wei Zhao
Journal:  ACS Med Chem Lett       Date:  2020-06-22       Impact factor: 4.345

8.  Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation.

Authors:  Wendy W C van Maren; Stefan Nierkens; Liza W Toonen; Judith M Bolscher; Roger P M Sutmuller; Gosse J Adema
Journal:  BMC Immunol       Date:  2011-03-24       Impact factor: 3.615

9.  Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2).

Authors:  Alexander N Shakhov; Vijay K Singh; Frederick Bone; Alec Cheney; Yevgeniy Kononov; Peter Krasnov; Troitza K Bratanova-Toshkova; Vera V Shakhova; Jason Young; Michael M Weil; Angela Panoskaltsis-Mortari; Christie M Orschell; Patricia S Baker; Andrei Gudkov; Elena Feinstein
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

10.  A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms.

Authors:  Ying-Chyi Song; Shih-Jen Liu
Journal:  Sci Rep       Date:  2015-07-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.